Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1 4Phase NA 2Phase 3 2Phase 1/2 2Phase 4 1

Status

Unknown 2Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Exercise 59Radiotherapy 49Blood Specimen Collection 45Radiosurgery 37Drug Therapy 35Standard of Care 32Surgical Procedures, Operative 30Magnetic Resonance Spectroscopy 26Laparoscopy 24Cisplatin 24Cyclophosphamide 23Control Groups 23Biopsy 23Acupuncture Therapy 23Magnetic Resonance Imaging 20Saline Solution 19Radiofrequency Ablation 19Endoscopic Mucosal Resection 19camrelizumab 16Surveys and Questionnaires 16Propofol 16Metformin 16Cytarabine 16anlotinib 15Preoperative Exercise 15Injections 15Fluorouracil 15Radiotherapy, Intensity-Modulated 14Neoadjuvant Therapy 14Early Intervention, Educational 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × Unknown × osimertinib × Clear all
NCT05583409 2022-10-17

SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC

Tongji Hospital

Phase NA Unknown
72 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04816838 2021-08-25

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations

Yonsei University

Phase NA Unknown
25 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡